{"product_id":"the-peripheral-t-cell-lymphomas-isbn-9781119671312","title":"The Peripheral T-Cell Lymphomas","description":"\u003cb\u003eTHE PERIPHERAL T-CELL LYMPHOMAS\u003c\/b\u003e \u003cp\u003e\u003cb\u003eProvides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003ePeripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. \u003c\/p\u003e\u003cp\u003eFor the first time in a single volume,\u003ci\u003e The Peripheral T-Cell Lymphomas \u003c\/i\u003epresents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCovers the biological basis, epidemiology, classification, and treatment of PTCL\u003c\/li\u003e\n\u003cli\u003eDiscusses the future of the field, including global collaboration efforts and novel approaches to PCTL\u003c\/li\u003e\n\u003cli\u003eExplores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation\u003c\/li\u003e\n\u003cli\u003eOffers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations\u003c\/li\u003e\n\u003cli\u003eFeatures contributions from the Chairs \u003ci\u003eThe T-Cell Lymphoma Forum\u003c\/i\u003e: the world’s largest meeting focused on PTCL\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eReflecting the unique epidemiology and genetic diversity of the PTCL, \u003ci\u003eThe Peripheral T-Cell Lymphomas \u003c\/i\u003eis an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice. \u003c\/p\u003e\u003cp\u003eContributors xix\u003c\/p\u003e \u003cp\u003eAbout the Companion Website xxiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Biological Basis of the Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 The Fundamentals of T-cell Lymphocyte Biology \u003c\/b\u003e\u003cb\u003e3\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eClaudio Tripodo and Stefano A. Pileri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 3\u003c\/p\u003e \u003cp\u003eGeneral View of the Differentiation and Function of T Lymphocytes 3\u003c\/p\u003e \u003cp\u003eThe T-cell System as a Frame for Peripheral T-cell Lymphoma: Taking Plasticity into Account 5\u003c\/p\u003e \u003cp\u003eMust Reads 7\u003c\/p\u003e \u003cp\u003eReferences 7\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Mechanisms of T-cell Lymphomagenesis \u003c\/b\u003e\u003cb\u003e9\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFrançois Lemonnier, Philippe Gaulard and Laurence de Leval\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 9\u003c\/p\u003e \u003cp\u003eOncogenic Events in the Transformation of T or Natural Killer Cells 9\u003c\/p\u003e \u003cp\u003eGenetic Lesions 9\u003c\/p\u003e \u003cp\u003eDeregulated Pathways in Peripheral T-cell Lymphoma Oncogenesis (Figure 2.1, Table 2.1) 10\u003c\/p\u003e \u003cp\u003eSignaling Pathways 13\u003c\/p\u003e \u003cp\u003eCell-cycle Control 14\u003c\/p\u003e \u003cp\u003eImmune Surveillance 14\u003c\/p\u003e \u003cp\u003eRole of the Microenvironment in Peripheral T-cell Lymphoma 15\u003c\/p\u003e \u003cp\u003eThe Model of Angio-immunoblastic T-cell Lymphoma and T Follicular Helper-derived Peripheral T-cell Lymphoma 15\u003c\/p\u003e \u003cp\u003eSpecific Microenvironment Components Present in Other Primary Cutaneous T-cell Lymphoma Entities 16\u003c\/p\u003e \u003cp\u003eUnderlying Factors Favoring the Tumor Transformation 18\u003c\/p\u003e \u003cp\u003eViruses 18\u003c\/p\u003e \u003cp\u003eChronic Antigenic Stimulation 19\u003c\/p\u003e \u003cp\u003eOther Factors 19\u003c\/p\u003e \u003cp\u003eCell of Origin (Table 2.1) 20\u003c\/p\u003e \u003cp\u003eConclusion 22\u003c\/p\u003e \u003cp\u003eMust Reads 22\u003c\/p\u003e \u003cp\u003eReferences 22\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Epigenetics of T-cell Lymphoma \u003c\/b\u003e\u003cb\u003e27\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eH. Miles Prince, Jasmine Zain, Anas Younes, Sean Whittaker, Owen A. O’Connor and Sean Harrop\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 27\u003c\/p\u003e \u003cp\u003eEpigenetic Pathways Altered in T-cell Lymphoma 27\u003c\/p\u003e \u003cp\u003eEpigenetic Changes Within Specific T-cell Lymphoma Subtypes 31\u003c\/p\u003e \u003cp\u003ePeripheral T-cell Lymphoma Not Otherwise Specified 32\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma and Peripheral T-cell Lymphoma with T Follicular Helper Phenotype 32\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphoma 33\u003c\/p\u003e \u003cp\u003eAdult T-cell Leukemia\/Lymphoma 33\u003c\/p\u003e \u003cp\u003eIntestinal T-cell Lymphoma 34\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphomas 34\u003c\/p\u003e \u003cp\u003eExtranodal Natural Killer\/T-cell Lymphoma 34\u003c\/p\u003e \u003cp\u003eMycosis Fungoides and Sézary Syndrome 35\u003c\/p\u003e \u003cp\u003eEstablished and Emerging Drugs Targeting the T-cell Lymphoma Epigenome 35\u003c\/p\u003e \u003cp\u003eDNA Methyltransferase Inhibitors 35\u003c\/p\u003e \u003cp\u003eIsocitrate Dehydrogenase Inhibitors 36\u003c\/p\u003e \u003cp\u003eEZH2 Inhibitors 37\u003c\/p\u003e \u003cp\u003eBET Inhibitors 38\u003c\/p\u003e \u003cp\u003eProtein Arginine Methyltransferases Inhibitors 38\u003c\/p\u003e \u003cp\u003eCombination Therapies Involving Epigenetic Targeting Agents 38\u003c\/p\u003e \u003cp\u003eFuture Directions 38\u003c\/p\u003e \u003cp\u003eMust Reads 39\u003c\/p\u003e \u003cp\u003eReferences 39\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Animal Models of T-cell Lymphoma \u003c\/b\u003e\u003cb\u003e47\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKeiichiro Hattori, Raksha Shrestha, Tatsuhiro Sakamoto, Manabu Kusakabe and Mamiko Sakata-Yanagimoto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 47\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma 50\u003c\/p\u003e \u003cp\u003eThe ROQUIN Mouse Model 50\u003c\/p\u003e \u003cp\u003eThe Mouse Models Recapitulating Human Angioimmunoblastic T-cell Lymphoma Genomic Features 50\u003c\/p\u003e \u003cp\u003eTet2 Gene Trap Mice 50\u003c\/p\u003e \u003cp\u003eG17V RHOA Mouse Model 50\u003c\/p\u003e \u003cp\u003ePDX Models of Angioimmunoblastic T-cell Lymphoma 51\u003c\/p\u003e \u003cp\u003eAnaplastic Large T-cell Lymphoma 51\u003c\/p\u003e \u003cp\u003eViral and Chimeric Models 51\u003c\/p\u003e \u003cp\u003eTransgenic Models 51\u003c\/p\u003e \u003cp\u003eCRISPR-Based Models 52\u003c\/p\u003e \u003cp\u003ePDX Models of Anaplastic Large-Cell Lymphomas 52\u003c\/p\u003e \u003cp\u003eHuman T-cell Lymphotropic Virus Type 1 Adult T-cell Leukemia\/Lymphoma 52\u003c\/p\u003e \u003cp\u003eMice Expressing HTLV-1 Viral Proteins 52\u003c\/p\u003e \u003cp\u003ePDX Models of Adult T-cell Leukemia\/Lymphoma 52\u003c\/p\u003e \u003cp\u003eCutaneous T-cell Lymphoma 53\u003c\/p\u003e \u003cp\u003eEnteropathy-associated T-cell Lymphoma 53\u003c\/p\u003e \u003cp\u003eConclusion 53\u003c\/p\u003e \u003cp\u003eMust Reads 53\u003c\/p\u003e \u003cp\u003eReferences 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Epidemiology and Classification of the PTCL \u003c\/b\u003e\u003cb\u003e57\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Geographic Distribution of the Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e59\u003cbr\u003e\u003c\/b\u003eGlobal Epidemiology\u003c\/p\u003e \u003cp\u003e\u003ci\u003eAmulya Yellala, Avyakta Kallam and James O. Armitage\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eHistorical Perspective 59\u003c\/p\u003e \u003cp\u003eEpidemiology 60\u003c\/p\u003e \u003cp\u003ePeripheral T-cell Lymphoma, Not Otherwise Specified 60\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma 61\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphoma 61\u003c\/p\u003e \u003cp\u003eAdult T-cell Lymphoma\/Leukemia (HTLV Associated) 62\u003c\/p\u003e \u003cp\u003eExtranodal NK\/T-cell Lymphomas 62\u003c\/p\u003e \u003cp\u003eT-cell Prolymphocytic Leukemia 62\u003c\/p\u003e \u003cp\u003eLarge Granular Lymphocytic Leukemia 62\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Gamma\/Delta PTCL 63\u003c\/p\u003e \u003cp\u003eEnteropathy Associated T-cell Lymphomas and Monomorphic Epitheliotropic Intestinal T-cell lymphoma 63\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphoma 63\u003c\/p\u003e \u003cp\u003eThe Cutaneous T-cell Lymphomas 63\u003c\/p\u003e \u003cp\u003eConclusion 63\u003c\/p\u003e \u003cp\u003eMust Reads 64\u003c\/p\u003e \u003cp\u003eReferences 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Classification of the Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e69\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNeval Ozkaya and Elaine S. Jaffe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 69\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T follicular Helper Cell Origin 69\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma 70\u003c\/p\u003e \u003cp\u003eFollicular T-cell Lymphoma 71\u003c\/p\u003e \u003cp\u003eNodal Peripheral T-cell Lymphoma with T-follicular Helper Phenotype 71\u003c\/p\u003e \u003cp\u003ePeripheral T-cell Lymphoma Not Otherwise Specified 71\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphomas 72\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphoma, ALK-Positive 72\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphoma, ALK-Negative 72\u003c\/p\u003e \u003cp\u003eBreast Implant-associated Anaplastic Large-cell Lymphoma (Provisional) 73\u003c\/p\u003e \u003cp\u003eAdult T-cell Leukemia\/Lymphoma 74\u003c\/p\u003e \u003cp\u003eIntestinal T-cell Lymphomas 74\u003c\/p\u003e \u003cp\u003eEnteropathy-associated T-Cell Lymphoma 75\u003c\/p\u003e \u003cp\u003eMonomorphic Epitheliotropic Intestinal T-cell Lymphoma 76\u003c\/p\u003e \u003cp\u003eIntestinal T-cell ymphoma, Not Otherwise Specified 76\u003c\/p\u003e \u003cp\u003eIndolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract (Provisional) 77\u003c\/p\u003e \u003cp\u003eNK-Cell Enteropathy 78\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphoma 78\u003c\/p\u003e \u003cp\u003eMycosis Fungoides 78\u003c\/p\u003e \u003cp\u003eSézary Syndrome 79\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous CD30-positive T-cell Lymphoproliferative Disorders 79\u003c\/p\u003e \u003cp\u003eLymphomatoid Papulosis 79\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Anaplastic Large-cell Lymphoma 80\u003c\/p\u003e \u003cp\u003eSubcutaneous Panniculitis-like T-cell Lymphoma 80\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Gamma–Delta T-cell Lymphoma 80\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma (Provisional) 81\u003c\/p\u003e \u003cp\u003ePrimary\u003c\/p\u003e \u003cp\u003eCutaneous CD4+ Small\/Medium T-Cell Lymphoproliferative Disorder (Provisional) 81\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Acral CD8+ T-cell Lymphoma (Provisional) 82\u003c\/p\u003e \u003cp\u003eLarge Granular Lymphocytic Leukemia 82\u003c\/p\u003e \u003cp\u003eT-cell Large Granular Lymphocytic Leukemia 82\u003c\/p\u003e \u003cp\u003eChronic Lymphoproliferative Disorder of NK Cells (Provisional) 82\u003c\/p\u003e \u003cp\u003eT-cell Prolymphocytic Leukemia 82\u003c\/p\u003e \u003cp\u003eNK-cell Lymphomas 83\u003c\/p\u003e \u003cp\u003eExtranodal NK\/T-cell Lymphoma, Nasal Type 83\u003c\/p\u003e \u003cp\u003eAggressive NK-cell Leukemia 83\u003c\/p\u003e \u003cp\u003eEBV-positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood 83\u003c\/p\u003e \u003cp\u003eMust Reads 84\u003c\/p\u003e \u003cp\u003eReferences 84\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Molecular Classification of the Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e91\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTyler A. Herek and Javeed Iqbal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 91\u003c\/p\u003e \u003cp\u003eT-cell Development and Activation: An Overview 92\u003c\/p\u003e \u003cp\u003eT-cell Receptor Signaling 92\u003c\/p\u003e \u003cp\u003eDerivation of Diagnostic Signatures for Molecular Classification of Peripheral T-cell Lymphomas 95\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T-cell Lymphoma and Other T Follicular Helper-derived Malignancies 95\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features 96\u003c\/p\u003e \u003cp\u003eAnaplastic Large-cell Lymphomas 96\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features 96\u003c\/p\u003e \u003cp\u003eAdult T-cell Leukemia\/Lymphoma 97\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features 97\u003c\/p\u003e \u003cp\u003ePeripheral T-cell Lymphoma Not Otherwise Specified 97\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features in Two Novel Subgroups 98\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphoma 98\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features 98\u003c\/p\u003e \u003cp\u003eExtranodal natural killer\/T-cell Lymphoma 98\u003c\/p\u003e \u003cp\u003eRecurrent Genetic Features 99\u003c\/p\u003e \u003cp\u003eCutaneous T-cell Lymphomas 99\u003c\/p\u003e \u003cp\u003eConclusion 99\u003c\/p\u003e \u003cp\u003eMust Reads 99\u003c\/p\u003e \u003cp\u003eReferences 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Discrete Clinical Subtypes of PTCL (Unique Epidemiology, Therapy and Management) \u003c\/b\u003e\u003cb\u003e105\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Peripheral T-cell Lymphoma Not Otherwise Specified \u003c\/b\u003e\u003cb\u003e107\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eN. Nora Bennani and Stephen M. Ansell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 107\u003c\/p\u003e \u003cp\u003eEpidemiology, Risk Factors, and Clinical Characteristics 107\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 108\u003c\/p\u003e \u003cp\u003ePrognostic Tools 109\u003c\/p\u003e \u003cp\u003eFrontline Therapy 110\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease 111\u003c\/p\u003e \u003cp\u003eFuture Directions 112\u003c\/p\u003e \u003cp\u003eMust Reads 112\u003c\/p\u003e \u003cp\u003eReferences 112\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Angioimmunoblastic T-cell Lymphoma \u003c\/b\u003e\u003cb\u003e115\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJehan Dupuis and Franck Morschhauser\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 115\u003c\/p\u003e \u003cp\u003eClinical and Biological Presentation 115\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors, Disease Incidence and Prevalence 117\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 118\u003c\/p\u003e \u003cp\u003eTET2 Mutations 119\u003c\/p\u003e \u003cp\u003eIDH2 Mutations 120\u003c\/p\u003e \u003cp\u003eDNMT3A Mutations 120\u003c\/p\u003e \u003cp\u003eRho A Mutations 121\u003c\/p\u003e \u003cp\u003eCD28 Alterations 121\u003c\/p\u003e \u003cp\u003eOther Mutations Affecting the T-cell Lymphoma Pathway 121\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 122\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease 122\u003c\/p\u003e \u003cp\u003eConventional Chemotherapy Agents 123\u003c\/p\u003e \u003cp\u003eBendamustine 123\u003c\/p\u003e \u003cp\u003ePralatrexate 123\u003c\/p\u003e \u003cp\u003eRomidepsin 124\u003c\/p\u003e \u003cp\u003eBelinostat 124\u003c\/p\u003e \u003cp\u003eNewer Targeted Therapy Approaches 125\u003c\/p\u003e \u003cp\u003eFuture Directions 125\u003c\/p\u003e \u003cp\u003eMust Reads 126\u003c\/p\u003e \u003cp\u003eReferences 126\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 The Spectrum of Anaplastic Large-cell Lymphoma \u003c\/b\u003e\u003cb\u003e129\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJianping Kong and Andrew L. Feldman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 129\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 129\u003c\/p\u003e \u003cp\u003eDisease Incidence and Prevalence 131\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 133\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 134\u003c\/p\u003e \u003cp\u003eManagement of the Relapsed or Refractory Patient 137\u003c\/p\u003e \u003cp\u003eFuture Directions 138\u003c\/p\u003e \u003cp\u003eAcknowledgement 140\u003c\/p\u003e \u003cp\u003eMust Reads 140\u003c\/p\u003e \u003cp\u003eReferences 140\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Human T-cell Lymphotropic Virus Type 1 Positive Adult T-cell Leukemia\/Lymphoma \u003c\/b\u003e\u003cb\u003e145\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWataru Munakata and Kensei Tobinai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEpidemiology and Disease Incidence 145\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 145\u003c\/p\u003e \u003cp\u003eCCR4 and Adult T-cell Leukemia\/Lymphoma 146\u003c\/p\u003e \u003cp\u003eClinical Features of Adult T-cell Leukemia\/Lymphoma 146\u003c\/p\u003e \u003cp\u003ePrognosis and Prognostic Index of ATLL 147\u003c\/p\u003e \u003cp\u003eFront-line Management of Aggressive Adult T-cell Leukemia\/Lymphoma 149\u003c\/p\u003e \u003cp\u003eChemotherapy and Hematopoietic Stem-cell Transplantation 149\u003c\/p\u003e \u003cp\u003eMogamulizumab with Dose-intensified Chemotherapy 150\u003c\/p\u003e \u003cp\u003eInterferon alpha and Antiretroviral Agents 151\u003c\/p\u003e \u003cp\u003eChemotherapy in Transplant-ineligible Patients with Aggressive Adult T-cell Leukemia\/Lymphoma 151\u003c\/p\u003e \u003cp\u003eFront-line Management of Indolent ATLL 152\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Patients 152\u003c\/p\u003e \u003cp\u003eMogamulizumab Monotherapy 152\u003c\/p\u003e \u003cp\u003eLenalidomide Monotherapy 153\u003c\/p\u003e \u003cp\u003eOther Treatments for Relapsed or Refractory Adult T-cell Leukemia\/Lymphoma 153\u003c\/p\u003e \u003cp\u003eFuture Directions 154\u003c\/p\u003e \u003cp\u003eMust Reads 154\u003c\/p\u003e \u003cp\u003eReferences 154\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Natural Killer\/T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e159\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSeok Jin Kim, Ritsuro Suzuki, Arnaud Jaccard, Soon Thye Lim and Wong Seog Kim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 159\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 161\u003c\/p\u003e \u003cp\u003eDisease Incidence and Prevalence 161\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 161\u003c\/p\u003e \u003cp\u003eGenetic Susceptibility to NK\/T-Cell Lymphoma 161\u003c\/p\u003e \u003cp\u003eMolecular Pathogenesis 162\u003c\/p\u003e \u003cp\u003eJAK–STAT and Associated Pathways 162\u003c\/p\u003e \u003cp\u003eNuclear Factor Kappa B and Other Deregulated Pathways 163\u003c\/p\u003e \u003cp\u003eThe Programmed Cell Death 1\/Programmed Death Ligand 1 Pathway 163\u003c\/p\u003e \u003cp\u003eManagement of Newly Diagnosed Treatment-naïve Patients 163\u003c\/p\u003e \u003cp\u003eDiagnosis and Initial Assessment 164\u003c\/p\u003e \u003cp\u003eMonitoring the Response 165\u003c\/p\u003e \u003cp\u003eTreatment Strategies 165\u003c\/p\u003e \u003cp\u003eLocalized Disease 165\u003c\/p\u003e \u003cp\u003eDisseminated Disease 167\u003c\/p\u003e \u003cp\u003eConsolidation Treatment with Hematopoietic Stem-cell Transplantation 167\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease 167\u003c\/p\u003e \u003cp\u003eTreatment of Localized Nasal Relapse 167\u003c\/p\u003e \u003cp\u003eTreatment of a Systemic Relapse 167\u003c\/p\u003e \u003cp\u003eNovel Agents for Relapsed or Refractory ENKTL 168\u003c\/p\u003e \u003cp\u003eFuture Directions 168\u003c\/p\u003e \u003cp\u003eMust Reads 168\u003c\/p\u003e \u003cp\u003eReferences 169\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 T-Prolymphocytic Leukemia \u003c\/b\u003e\u003cb\u003e175\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDima El-Sharkawi and Claire Dearden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 175\u003c\/p\u003e \u003cp\u003eIncidence 175\u003c\/p\u003e \u003cp\u003eClinical Features 175\u003c\/p\u003e \u003cp\u003eLaboratory Findings 175\u003c\/p\u003e \u003cp\u003eTreatment 176\u003c\/p\u003e \u003cp\u003eStem-cell Transplantation 178\u003c\/p\u003e \u003cp\u003eTreatment for Relapsed\/Refractory Disease 178\u003c\/p\u003e \u003cp\u003eFuture Directions 178\u003c\/p\u003e \u003cp\u003eMust Reads 179\u003c\/p\u003e \u003cp\u003eReferences 179\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Large Granular Lymphocyte Leukemia \u003c\/b\u003e\u003cb\u003e183\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKarolina H. Dziewulska, Katharine B. Moosic, HeeJin Cheon, Kristine C. Olson, David J. Feith and Thomas P. Loughran, Jr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 183\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 183\u003c\/p\u003e \u003cp\u003ePrevalence of Concomitant Disorders 184\u003c\/p\u003e \u003cp\u003eAutoimmune Diseases 184\u003c\/p\u003e \u003cp\u003eHematological Disorders 184\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 185\u003c\/p\u003e \u003cp\u003eBiology 185\u003c\/p\u003e \u003cp\u003eSTAT3 Dysregulation 185\u003c\/p\u003e \u003cp\u003eSTAT3 and Common Cytopenias 186\u003c\/p\u003e \u003cp\u003eJAK–STAT Pathway 187\u003c\/p\u003e \u003cp\u003eOther Mutated and Dysregulated Pathways 187\u003c\/p\u003e \u003cp\u003eChronic Activation and Large Granular Lymphocyte Clonal Malignancy 188\u003c\/p\u003e \u003cp\u003eSTAT3 and Clonality 188\u003c\/p\u003e \u003cp\u003eAntigenic Stimulation 188\u003c\/p\u003e \u003cp\u003eImmune System Dysregulation 189\u003c\/p\u003e \u003cp\u003eCytotoxic Killer Cells and Autoimmunity 189\u003c\/p\u003e \u003cp\u003eHumoral Abnormalities 189\u003c\/p\u003e \u003cp\u003eAbnormal Bone Marrow 190\u003c\/p\u003e \u003cp\u003eNeutropenia and Rheumatoid Arthritis 190\u003c\/p\u003e \u003cp\u003eSpleen Pathology 191\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 191\u003c\/p\u003e \u003cp\u003eDiagnosis 191\u003c\/p\u003e \u003cp\u003ePrognosis 191\u003c\/p\u003e \u003cp\u003eCurrent Treatments 192\u003c\/p\u003e \u003cp\u003eIndications for Treatment 192\u003c\/p\u003e \u003cp\u003eEvaluation of Treatment Response 192\u003c\/p\u003e \u003cp\u003eTherapeutic Approach 192\u003c\/p\u003e \u003cp\u003eCanonical Immunosuppressive Treatments 192\u003c\/p\u003e \u003cp\u003eNon-canonical Immunosuppressive Treatments 193\u003c\/p\u003e \u003cp\u003eSupportive Therapy 194\u003c\/p\u003e \u003cp\u003eSummary of Therapeutic Recommendations 194\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease 194\u003c\/p\u003e \u003cp\u003eFuture Directions 194\u003c\/p\u003e \u003cp\u003eJAK–STAT Pathway Targeting 194\u003c\/p\u003e \u003cp\u003eNatural Compounds 196\u003c\/p\u003e \u003cp\u003eOther Candidate Agents 196\u003c\/p\u003e \u003cp\u003eFunding 196\u003c\/p\u003e \u003cp\u003eDisclosures 197\u003c\/p\u003e \u003cp\u003eMust Reads 197\u003c\/p\u003e \u003cp\u003eReferences 197\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Gamma–Delta T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e203\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFrancine Foss, Aadil Ahmed and Mina Xu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 203\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 203\u003c\/p\u003e \u003cp\u003eBiology of Primary Cutaneous Gamma–Delta T-cell Lymphoma 204\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 206\u003c\/p\u003e \u003cp\u003eManagement of Relapsed\/Refractory Disease 208\u003c\/p\u003e \u003cp\u003eMust Reads 209\u003c\/p\u003e \u003cp\u003eReferences 209\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Enteropathy-Associated and Monomorphic Epitheliotropic Intestinal T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e211\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCraig R. Soderquist, Jennifer Shingleton, Sandeep Dave and Govind Bhagat\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 211\u003c\/p\u003e \u003cp\u003eEnteropathy-associated T-cell Lymphoma 211\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 211\u003c\/p\u003e \u003cp\u003eDisease Incidence and Prevalence 212\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 212\u003c\/p\u003e \u003cp\u003eMorphology and Immunophenotype 212\u003c\/p\u003e \u003cp\u003eMolecular and Genetic Alterations 212\u003c\/p\u003e \u003cp\u003eManagement of Patients in the Front Line 213\u003c\/p\u003e \u003cp\u003eManagement of the Relapsed or Refractory Patient 214\u003c\/p\u003e \u003cp\u003eFuture Directions 214\u003c\/p\u003e \u003cp\u003eRefractory Celiac Disease 214\u003c\/p\u003e \u003cp\u003eDisease Definition, Risk Factors, Incidence, and Prevalence 214\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 214\u003c\/p\u003e \u003cp\u003eMorphology and Immunophenotype 214\u003c\/p\u003e \u003cp\u003eMolecular and Genetic Alterations 215\u003c\/p\u003e \u003cp\u003eManagement of Patients in the Front-Line 216\u003c\/p\u003e \u003cp\u003eManagement of the Relapsed or Refractory Patient 216\u003c\/p\u003e \u003cp\u003eFuture Directions 216\u003c\/p\u003e \u003cp\u003eMonomorphic Epitheliotropic Intestinal T-Cell Lymphoma 216\u003c\/p\u003e \u003cp\u003eDisease Risk Factors, Incidence, and Prevalence 216\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 216\u003c\/p\u003e \u003cp\u003eMorphology and Immunophenotype 216\u003c\/p\u003e \u003cp\u003eMolecular and Genetic Alterations 218\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 218\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease 218\u003c\/p\u003e \u003cp\u003eFuture Directions 218\u003c\/p\u003e \u003cp\u003eMust Reads 218\u003c\/p\u003e \u003cp\u003eReferences 219\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Hepatosplenic T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e225\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRobert N. Stuver, Mwanasha Merrill and Salvia Jain\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEpidemiology and Disease Incidence 225\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 227\u003c\/p\u003e \u003cp\u003eClinical Features 227\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 228\u003c\/p\u003e \u003cp\u003eManagement of the Relapsed or Refractory Disease 229\u003c\/p\u003e \u003cp\u003eSplenectomy 230\u003c\/p\u003e \u003cp\u003eFuture Directions 230\u003c\/p\u003e \u003cp\u003eFunding 231\u003c\/p\u003e \u003cp\u003eMust Reads 231\u003c\/p\u003e \u003cp\u003eReferences 231\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Cutaneous T-cell Lymphoma \u003c\/b\u003e\u003cb\u003e235\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAlejandro A. Gru, Bethanie Rooke, Kevin Molloy and Julia Scarisbrick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 35\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 236\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 237\u003c\/p\u003e \u003cp\u003eClinical, Pathologic, and Immunophenotypic Findings 240\u003c\/p\u003e \u003cp\u003eManagement of Front-Line Mycosis Fungoides\/Sézary Syndrome 247\u003c\/p\u003e \u003cp\u003eEarly-stage Disease (Stages IA–IIA) 248\u003c\/p\u003e \u003cp\u003eLate-stage Disease (Stage IIB–IVA2) 250\u003c\/p\u003e \u003cp\u003eStage IIB (Tumor-stage Disease) 250\u003c\/p\u003e \u003cp\u003eStage III–IVA1 Disease (Erythrodermic Disease and Sézary) 250\u003c\/p\u003e \u003cp\u003eStage IVA2–IVB Disease 250\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Disease with Mycosis Fungoides\/Sézary Syndrome 250\u003c\/p\u003e \u003cp\u003eEarly-stage Disease (Stage IA–IIA) 250\u003c\/p\u003e \u003cp\u003eLate-stage Disease (IIB–IVA2) 251\u003c\/p\u003e \u003cp\u003eStage IIB (Tumor-stage Disease) 251\u003c\/p\u003e \u003cp\u003eStage III–IVA1 (Erythrodermic Disease) 251\u003c\/p\u003e \u003cp\u003eStage IVA2–IVB Disease 252\u003c\/p\u003e \u003cp\u003eFront-Line Management of Non-mycosis Fungoides Cutaneous T-cell Lymphomas 252\u003c\/p\u003e \u003cp\u003eManagement of Relapsed or Refractory Non-mycosis Fungoides Cutaneous T-cell Lymphomas 252\u003c\/p\u003e \u003cp\u003eFuture Directions 252\u003c\/p\u003e \u003cp\u003eMust Reads 253\u003c\/p\u003e \u003cp\u003eReferences 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Other Rare Subtypes of Peripheral T-cell Lymphoma \u003c\/b\u003e\u003cb\u003e259\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePier Paolo Piccaluga\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 259\u003c\/p\u003e \u003cp\u003eChronic Lymphoproliferative Disorders of Natural Killer Cells 259\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 259\u003c\/p\u003e \u003cp\u003eDisease Incidence and Prevalence 259\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 260\u003c\/p\u003e \u003cp\u003eManagement of Front-line Disease 260\u003c\/p\u003e \u003cp\u003eEpstein–Barr Virus-associated T-cell and NK-cell Lymphoproliferative Disorders of Childhood 260\u003c\/p\u003e \u003cp\u003eSystemic Epstein–Barr Virus-positive T-cell Lymphoma of Childhood 260\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 260\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 260\u003c\/p\u003e \u003cp\u003eManagement of Front-Line Disease 261\u003c\/p\u003e \u003cp\u003eChronic Active Epstein–Barr Virus Infection of T- and NK-cell Type, Systemic Form 261\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 261\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 261\u003c\/p\u003e \u003cp\u003eManagement of Front-Line Disease 262\u003c\/p\u003e \u003cp\u003eChronic Active Epstein–Barr Virus Infection of T- and NK-cell Type, Cutaneous Form 264\u003c\/p\u003e \u003cp\u003eHydroa Vacciniforme-like Lymphoproliferative Disorder 264\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 264\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front Line 264\u003c\/p\u003e \u003cp\u003eSevere Mosquito Bite Allergy 265\u003c\/p\u003e \u003cp\u003eEpidemiology and Risk Factors 265\u003c\/p\u003e \u003cp\u003eBasic Principles of Disease Biology 265\u003c\/p\u003e \u003cp\u003eManagement of Disease in the Front-Line 265\u003c\/p\u003e \u003cp\u003eFuture Directions 265\u003c\/p\u003e \u003cp\u003eMust Reads 265\u003c\/p\u003e \u003cp\u003eReferences 266\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Treatment of the PTCL \u003c\/b\u003e\u003cb\u003e269\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Standard Front-line Therapies \u003c\/b\u003e\u003cb\u003e271\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRaphael Koch and Lorenz Truempe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 271\u003c\/p\u003e \u003cp\u003eInitial Workup and Risk Stratification 271\u003c\/p\u003e \u003cp\u003eFront-line Therapy 274\u003c\/p\u003e \u003cp\u003eFront-line Treatment Approaches for Common Subtypes 274\u003c\/p\u003e \u003cp\u003eSystemic Anaplastic Large-cell Lymphomas 276\u003c\/p\u003e \u003cp\u003eBreast Implant-associated Anaplastic Large-cell Lymphomas 277\u003c\/p\u003e \u003cp\u003eEnteropathy-associated T-cell Lymphoma and Monomorphic Epitheliotropic Intestinal T-cell Lymphoma 277\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphoma 278\u003c\/p\u003e \u003cp\u003eExtranodal natural killer\/T-cell Lymphoma, Nasal Type 279\u003c\/p\u003e \u003cp\u003eT-cell Prolymphocytic Leukemia 280\u003c\/p\u003e \u003cp\u003eAdult T-Cell Leukemia\/Lymphoma 280\u003c\/p\u003e \u003cp\u003eMust Reads 281\u003c\/p\u003e \u003cp\u003eReferences 281\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin \u003c\/b\u003e\u003cb\u003e287\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHelen Ma and Owen A. O’Connor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 287\u003c\/p\u003e \u003cp\u003eChallenges in Developing New Drugs in Peripheral T-cell Lymphomas 288\u003c\/p\u003e \u003cp\u003eDrugs Approved by the US Food and Drug Administration with an Indication in Relapsed\/Refractory Peripheral T-cell Lymphoma 288\u003c\/p\u003e \u003cp\u003ePralatrexate 289\u003c\/p\u003e \u003cp\u003ePharmacology 289\u003c\/p\u003e \u003cp\u003eEarly-phase Data 289\u003c\/p\u003e \u003cp\u003ePivotal Data 289\u003c\/p\u003e \u003cp\u003eRecent Developments 291\u003c\/p\u003e \u003cp\u003eHistone Deacetylase Inhibitors (Including Romidepsin and Belinostat) 291\u003c\/p\u003e \u003cp\u003ePharmacology 291\u003c\/p\u003e \u003cp\u003eEarly Phase Data 292\u003c\/p\u003e \u003cp\u003ePivotal Data 292\u003c\/p\u003e \u003cp\u003eRecent Developments 293\u003c\/p\u003e \u003cp\u003eDrugs Approved by the US Food and Drug Administration But Without An Indication in Relapsed\/Refractory Peripheral T-cell Lymphoma 294\u003c\/p\u003e \u003cp\u003eEtoposide 294\u003c\/p\u003e \u003cp\u003ePharmacology 294\u003c\/p\u003e \u003cp\u003eClinical Experiences in Peripheral T-cell Lymphoma 294\u003c\/p\u003e \u003cp\u003eSummary 294\u003c\/p\u003e \u003cp\u003eBortezomib 294\u003c\/p\u003e \u003cp\u003ePharmacology 294\u003c\/p\u003e \u003cp\u003eClinical Experiences in Peripheral T-cell Lymphoma 296\u003c\/p\u003e \u003cp\u003eRecent Developments 296\u003c\/p\u003e \u003cp\u003eBendamustine 296\u003c\/p\u003e \u003cp\u003ePharmacology 296\u003c\/p\u003e \u003cp\u003eClinical Experience in Peripheral T-cell Lymphoma 296\u003c\/p\u003e \u003cp\u003eRecent Developments 296\u003c\/p\u003e \u003cp\u003eGemcitabine 296\u003c\/p\u003e \u003cp\u003ePharmacology 296\u003c\/p\u003e \u003cp\u003eClinical Data 297\u003c\/p\u003e \u003cp\u003eRecent Developments 297\u003c\/p\u003e \u003cp\u003eDrugs Approved by International Regulatory Agencies, Not Including the United States, that Carry an Indication in Relapsed\/Refractory Peripheral T-cell Lymphoma 297\u003c\/p\u003e \u003cp\u003eChidamide 297\u003c\/p\u003e \u003cp\u003ePharmacology 297\u003c\/p\u003e \u003cp\u003eEarly Phase Data 297\u003c\/p\u003e \u003cp\u003ePivotal Data 297\u003c\/p\u003e \u003cp\u003eRecent Developments 297\u003c\/p\u003e \u003cp\u003eForodesine 297\u003c\/p\u003e \u003cp\u003ePharmacology 297\u003c\/p\u003e \u003cp\u003eEarly Phase Data 297\u003c\/p\u003e \u003cp\u003ePivotal Data 298\u003c\/p\u003e \u003cp\u003eRecent Developments 298\u003c\/p\u003e \u003cp\u003eConsiderations in the Selection of Therapy 298\u003c\/p\u003e \u003cp\u003eTreatment Goals 298\u003c\/p\u003e \u003cp\u003eAggressive Versus Indolent Disease 299\u003c\/p\u003e \u003cp\u003eTransplant Eligible or Ineligible 299\u003c\/p\u003e \u003cp\u003eSuitability for Chemotherapy 299\u003c\/p\u003e \u003cp\u003eConclusion 299\u003c\/p\u003e \u003cp\u003eMust Reads 299\u003c\/p\u003e \u003cp\u003eReferences 300\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 The Role of Autologous Stem-cell Transplantation in Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e305\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJuan Alejandro Ospina-Idárraga, Rolando Humberto Martinez-Cordero, Leonardo José Enciso-Olivera and Henry Idrobo-Quintero\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 305\u003c\/p\u003e \u003cp\u003eAutologous Stem-cell Transplantation in First Complete Remission 306\u003c\/p\u003e \u003cp\u003eAutologous Stem-cell Transplantation in Relapsed\/Refractory Disease 307\u003c\/p\u003e \u003cp\u003eInterpretation of Available Literature 307\u003c\/p\u003e \u003cp\u003eIdentifying the Most Relevant Determinants for Survival among Patients with Peripheral T-cell Lymphoma Undergoing Autologous Stem-cell Transplantation 308\u003c\/p\u003e \u003cp\u003eStatus of Response Prior to Autologous Stem-cell Transplantation 309\u003c\/p\u003e \u003cp\u003eRisk of Stage 310\u003c\/p\u003e \u003cp\u003eNumber of Prior Therapies and Refractory Disease 311\u003c\/p\u003e \u003cp\u003eAutologous Stem-cell Transplantation on Specific Subtypes of Peripheral T-cell Lymphoma 311\u003c\/p\u003e \u003cp\u003ePeripheral T-cell Lymphomas Not Otherwise Specified 311\u003c\/p\u003e \u003cp\u003eAngioimmunoblastic T Cell Lymphoma 312\u003c\/p\u003e \u003cp\u003eAnaplastic T Large-cell Lymphoma 312\u003c\/p\u003e \u003cp\u003eExtranodal Natural Killer\/T-cell Lymphoma, Nasal Type 313\u003c\/p\u003e \u003cp\u003eThe Role of Autologous Stem-cell Transplantation in Cutaneous T-cell Lymphomas 314\u003c\/p\u003e \u003cp\u003eMust Reads 314\u003c\/p\u003e \u003cp\u003eReferences 315\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Allogeneic Stem-cell Transplantation \u003c\/b\u003e\u003cb\u003e319\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAnna Dodero and Paolo Corradini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 319\u003c\/p\u003e \u003cp\u003eAllogeneic Stem-cell Transplantation for Relapsed and\u003c\/p\u003e \u003cp\u003eRefractory Disease (Focus on Nodal Hystotypes) 320\u003c\/p\u003e \u003cp\u003eAllogeneic Stem-cell Transplantation as Consolidation of First Remission 322\u003c\/p\u003e \u003cp\u003eAllogeneic Stem-cell Transplantation in Specific Subtypes 322\u003c\/p\u003e \u003cp\u003eCutaneous T-cell Lymphomas 322\u003c\/p\u003e \u003cp\u003eHepatosplenic T-cell Lymphomas 324\u003c\/p\u003e \u003cp\u003eExtranodal Natural Killer\/T-cell Lymphomas, Nasal Type 324\u003c\/p\u003e \u003cp\u003eAdult T-cell Leukemia\/Lymphoma 324\u003c\/p\u003e \u003cp\u003eFuture Directions 325\u003c\/p\u003e \u003cp\u003eMust Reads 325\u003c\/p\u003e \u003cp\u003eReferences 325\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Emerging Immunotherapy Approaches in Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e329\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBarbara Pro and Andrei Shustov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 329\u003c\/p\u003e \u003cp\u003eMonoclonal Antibody Therapy 329\u003c\/p\u003e \u003cp\u003eAlemtuzumab 330\u003c\/p\u003e \u003cp\u003eMogamulizumab 330\u003c\/p\u003e \u003cp\u003eImmunoconjugate-Based Therapy for Peripheral T-Cell Lymphoma 331\u003c\/p\u003e \u003cp\u003eBrentuximab Vedotin 332\u003c\/p\u003e \u003cp\u003eCell-Mediated or Cellular Immunotherapy in Peripheral T-Cell Lymphoma 333\u003c\/p\u003e \u003cp\u003ePD1–PD-L1 Checkpoint Inhibition 334\u003c\/p\u003e \u003cp\u003eAFM13 – Targeted Natural Killer Cell Immunotherapy Facilitator 335\u003c\/p\u003e \u003cp\u003eTTI-621 – Targeted Macrophage Immunotherapy Facilitator 335\u003c\/p\u003e \u003cp\u003e4-1BB – Enabled Adoptive Therapy of Epstein–Barr Virus-Positive Malignancies 335\u003c\/p\u003e \u003cp\u003eIPH4102 (Anti-KIR3DL2 Monoclonal Antibody) 336\u003c\/p\u003e \u003cp\u003eChimeric Antigen Receptor T-cell Therapy for Peripheral T-cell Lymphoma 336\u003c\/p\u003e \u003cp\u003eChallenges and Future Directions 336\u003c\/p\u003e \u003cp\u003eMust Reads 337\u003c\/p\u003e \u003cp\u003eReferences 338\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Emerging New Small Molecules in Peripheral T-cell Lymphomas \u003c\/b\u003e\u003cb\u003e343\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eAlessandro Broccoli and Pier Luigi Zinzani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 343\u003c\/p\u003e \u003cp\u003eDemethylating Agents 344\u003c\/p\u003e \u003cp\u003eJanus-associated Kinase–Signal Transducers and Activators of Transcription and Spleen Tyrosine Kinase Inhibitors 345\u003c\/p\u003e \u003cp\u003ePhosphatidylinositol 3-Kinase Inhibitors 345\u003c\/p\u003e \u003cp\u003eMiscellaneous 347\u003c\/p\u003e \u003cp\u003ePro-apoptotic Small Molecules 347\u003c\/p\u003e \u003cp\u003eFarnesyltransferase Inhibitors 347\u003c\/p\u003e \u003cp\u003eAurora Kinase Inhibitors 347\u003c\/p\u003e \u003cp\u003eConclusion 348\u003c\/p\u003e \u003cp\u003eMust Reads 348\u003c\/p\u003e \u003cp\u003eReferences 348\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Future Directions \u003c\/b\u003e\u003cb\u003e351\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 The Value and Relevance of T-cell Lymphoma Registries \u003c\/b\u003e\u003cb\u003e353\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eTetiana Skrypets, Martina Manni, Monica Civallero, Iryna Kriachok and Massimo Federico\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 353\u003c\/p\u003e \u003cp\u003ePopulation-based Cancer Registries 353\u003c\/p\u003e \u003cp\u003eRetrospective Studies 355\u003c\/p\u003e \u003cp\u003eT-cell Lymphoma Registries 360\u003c\/p\u003e \u003cp\u003eT-cell Project 1.0 360\u003c\/p\u003e \u003cp\u003eCOMPLETE 363\u003c\/p\u003e \u003cp\u003eT-cell Project 2.0 363\u003c\/p\u003e \u003cp\u003eFuture Directions 364\u003c\/p\u003e \u003cp\u003eDisclosures 364\u003c\/p\u003e \u003cp\u003eMust Reads 364\u003c\/p\u003e \u003cp\u003eReferences 365\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Innovative Chemotherapy-free Approaches for the Treatment of Peripheral T-Cell Lymphoma \u003c\/b\u003e\u003cb\u003e367\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eEnrica Marchi, Ahmed Sawas, Helen Ma, Luigi Scotto and Francesca Montanari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 367\u003c\/p\u003e \u003cp\u003eTargeting the Peripheral T-cell Lymphoma Epigenome 369\u003c\/p\u003e \u003cp\u003eRomidepsin Plus Pralatrexate 370\u003c\/p\u003e \u003cp\u003ePreclinical Rationale 370\u003c\/p\u003e \u003cp\u003eClinical Experience 370\u003c\/p\u003e \u003cp\u003eRomidepsin Plus 5-Azacytidine 371\u003c\/p\u003e \u003cp\u003ePreclinical Rationale 371\u003c\/p\u003e \u003cp\u003eClinical Experience 371\u003c\/p\u003e \u003cp\u003eRomidepsin Plus Duvelisib 372\u003c\/p\u003e \u003cp\u003ePreclinical Rationale 372\u003c\/p\u003e \u003cp\u003eClinical Experience 372\u003c\/p\u003e \u003cp\u003eRomidepsin Plus Lenalidomide 373\u003c\/p\u003e \u003cp\u003ePreclinical Rationale 373\u003c\/p\u003e \u003cp\u003eClinical Experience 373\u003c\/p\u003e \u003cp\u003ePanobinostat and Bortezomib 373\u003c\/p\u003e \u003cp\u003ePreclinical Rationale 373\u003c\/p\u003e \u003cp\u003eClinical Experience 374\u003c\/p\u003e \u003cp\u003eA Glance at the Future: Building on the Active Doublets 374\u003c\/p\u003e \u003cp\u003eMust Reads 375\u003c\/p\u003e \u003cp\u003eReferences 375\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Global Collaborations \u003c\/b\u003e\u003cb\u003e379\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDejan Radjeski, Eliza Hawke, Owen A. O’Connor, Pier Luigi Zinzani, Won Seog Kim and Enrica Marchi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 379\u003c\/p\u003e \u003cp\u003eThe Global T-cell Lymphoma Consortium 380\u003c\/p\u003e \u003cp\u003eThe Mission 380\u003c\/p\u003e \u003cp\u003eStructure 380\u003c\/p\u003e \u003cp\u003eOrganizational Features 380\u003c\/p\u003e \u003cp\u003eSubmission of Trial Concepts 381\u003c\/p\u003e \u003cp\u003eBudget Negotiations 382\u003c\/p\u003e \u003cp\u003eInstitutional Review Board 383\u003c\/p\u003e \u003cp\u003ePublications 383\u003c\/p\u003e \u003cp\u003eConclusion 384\u003c\/p\u003e \u003cp\u003eIndex 385\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAbout the Editors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eOwen A. O’Connor, \u003c\/b\u003eAmerican Cancer Society Research Professor, Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Program for T-cell Lymphoma Research, Department of Microbiology, Immunology, and Cancer Research, University of Virginia Cancer Center, Charlottesville, VA, USA. \u003c\/p\u003e\u003cp\u003e\u003cb\u003eWon Seog Kim, MD, PhD \u003c\/b\u003eis Professor of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. \u003c\/p\u003e\u003cp\u003e\u003cb\u003ePier Luigi Zinzani, MD, PhD \u003c\/b\u003eis\u003cb\u003e \u003c\/b\u003eProfessor of Hematology\u003cb\u003e, \u003c\/b\u003eDirector of Lymphoma and CLL Unit, and\u003cb\u003e \u003c\/b\u003eChief of Phase I clinical trials\u003cb\u003e, \u003c\/b\u003eInstitute of Hematology, University of Bologna, Italy.  \u003c\/p\u003e\u003cp\u003e\u003cb\u003eProvides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePeripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. \u003c\/p\u003e\u003cp\u003eFor the first time in a single volume,\u003ci\u003e The Peripheral T-Cell Lymphomas \u003c\/i\u003epresents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eCovers the biological basis, epidemiology, classification, and treatment of PTCL\u003c\/li\u003e\n\u003cli\u003eDiscusses the future of the field, including global collaboration efforts and novel approaches to PCTL\u003c\/li\u003e\n\u003cli\u003eExplores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation\u003c\/li\u003e\n\u003cli\u003eOffers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations\u003c\/li\u003e\n\u003cli\u003eFeatures contributions from the Chairs \u003ci\u003eThe T-Cell Lymphoma Forum\u003c\/i\u003e: the world’s largest meeting focused on PTCL\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eReflecting the unique epidemiology and genetic diversity of the PTCL, \u003ci\u003eThe Peripheral T-Cell Lymphomas \u003c\/i\u003eis an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990308929765,"sku":"NP9781119671312","price":215.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119671312.jpg?v=1761787299","url":"https:\/\/k12savings.com\/es\/products\/the-peripheral-t-cell-lymphomas-isbn-9781119671312","provider":"K12savings","version":"1.0","type":"link"}